A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China.

Front Oncol · 2023 · PMC10800576 · PMID 38260846

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Hence, it is evident that while patients without BRCA-m may potentially benefit from niraparib in terms of PFS, there is a decreasing trend in OS.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.